6 unknown, 1 not yet recruiting. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Jinming Yu: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC Adebrelimab, Radiation Therapy - Extensive Stage Lung Small Cell Carcinoma | Phase 3 | Not yet recruiting | Jinming Yu | 524 | 2024-12-01 | 2024-11-05 |
| The Predictive Value of Proteome Profiling for Brain Metastasis in Limited-Stage Small-Cell Lung Cancer Small-cell Lung Cancer | Unknown | Jinming Yu | 228 | 2023-10-01 | 2024-07-03 | |
| Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer Iruplinalkib - Non-small Cell Lung Cancer (NSCLC) | Unknown | Jinming Yu | 5000 | 2023-07-24 | 2023-08-15 | |
| A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy TQB2450 Injection + Anlotinib Hydrochloride Capsules - Limited Stage Small Cell Lung Cancer, Not Progressed After First-line Chemoradiotherapy | Phase 1 | Unknown | Jinming Yu | 20 | 2023-05-30 | 2023-07-12 |
| WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC WX-0593 Tablets, chemotherapy, Thoracic Radiation Therapy（TRT） - Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Unknown | Jinming Yu | 40 | 2022-04-30 | 2022-04-28 |
| A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Pyrotinib, SHR6390, Letrozole - Metastatic Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Unknown | Jinming Yu | 60 | 2019-09-30 | 2019-09-19 |
| Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21 Erlotinib w Concurrent Radiotherapy, etoposide/cis-platin (EP) w Concurrent Radiotherapy - Non-small Cell Lung Cancer | Phase 2 | Unknown | Jinming Yu | 100 | 2012-12-14 | 2017-02-07 |
Carcinoma, Non-Small-Cell Lung (3) · Breast Neoplasms (1) · Small Cell Lung Carcinoma (1)
Capecitabine (1) · Drug Therapy (1) · Letrozole (1) · Radiation (1) · Radiotherapy (1) · pyrotinib (1)
China (6)
Baolin Qu, PhD (1) · Bing Lu, PhD (1) · Chun Han, PhD (1) · Conghua Xie, PhD (1) · Gang Wu, PhD (1) · Guang Li, PhD (1) · Guangying Zhu, PhD (1) · Jiancheng Li, PhD (1) · Jianhua Wang, PhD (1) · Lvhua Wang, PhD (1) · Ming Chen, PhD (1) · Qibin Song, PhD (1) · Qin Lin, PhD (1)